Krystal Biotech, Inc. is a gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases. The Companyâ€™s products include KB103 and KB104.The Company's KB103 is in preclinical development to treat dystrophic epidermolysis bullosa, or DEB, a rare and severe genetic disease. The Company's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness and dehydration.
Number of employees : 51 people.
|Vote ||Quantity||Float||Company-owned shares||Total Float
|Krish S. Krishnan ||1,936,462||
|Suma M. Krishnan ||1,936,064||
|Frazier Management LLC ||1,790,000||
|Fidelity Management & Research Co. ||1,148,286||
|Redmile Group LLC ||1,090,200||
|T. Rowe Price Associates, Inc. (Investment Management) ||1,050,585||
|Baker Bros. Advisors LP ||1,034,674||
|OrbiMed Advisors LLC ||994,808||
|Sun Pharmaceutical Industries Limited ||914,107||
|The Vanguard Group, Inc. ||593,125||
|Company contact information|
Sector Bio Therapeutic Drugs
Connections : Krystal Biotech, Inc.